Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD E MILLS

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1518919828
CMS profile
250796
Location
MT PLEASANT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,356.41

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,356.41 148

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD E MILLS

NPI 1518919828 · CMS profile ID 250796

Allopathic & Osteopathic Physicians / Internal Medicine

MT PLEASANT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $2,356.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $14.1708/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788341699 CMS
E.R. Squibb & Sons, L.L.C. $14.9207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783664613 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.0007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763535702 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.2807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820090057 CMS
Daiichi Sankyo Inc. $20.5007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836305815 CMS
Amgen Inc. $15.9707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825719983 CMS
AbbVie Inc. $9.4707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698345 CMS
AbbVie Inc. $14.1807/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698339 CMS
PFIZER INC. $12.4607/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832671415 CMS
Biohaven Pharmaceuticals, Inc. $17.9706/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852568283 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.1806/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763535704 CMS
Janssen Scientific Affairs, LLC $16.4706/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788341705 CMS
Gilead Sciences, Inc. $15.4506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848241825 CMS
AstraZeneca Pharmaceuticals LP $11.5206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829554839 CMS
Esperion Therapeutics, Inc. $19.2706/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838355635 CMS
Amgen Inc. $11.5906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825719967 CMS
Amgen Inc. $21.1106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825719979 CMS
Merck Sharp & Dohme Corporation $19.3906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848365165 CMS
GlaxoSmithKline, LLC. $16.8606/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803076505 CMS
Novo Nordisk Inc $19.6406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811579585 CMS
VIVUS LLC $14.9606/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814343941 CMS
AbbVie Inc. $11.7306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698335 CMS
PFIZER INC. $13.4606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832602691 CMS
Daiichi Sankyo Inc. $16.6706/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836300423 CMS
Lilly USA, LLC $19.6506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818712035 CMS
Amgen Inc. $13.4806/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825719955 CMS
E.R. Squibb & Sons, L.L.C. $17.9305/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783664589 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763535706 CMS
BOSTON SCIENTIFIC CORPORATION $14.7905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777698917 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.3605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850331391 CMS
Lilly USA, LLC $19.9005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818725061 CMS
Gilead Sciences, Inc. $16.1705/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848241823 CMS
GlaxoSmithKline, LLC. $30.3705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802281487 CMS
PFIZER INC. $15.8105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833545383 CMS
VIVUS LLC $12.7905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814343933 CMS
Biohaven Pharmaceuticals, Inc. $18.4305/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852568281 CMS
AbbVie Inc. $12.0605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698329 CMS
GlaxoSmithKline, LLC. $14.9904/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803023223 CMS
Amarin Pharma Inc. $15.2104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815059895 CMS
AbbVie Inc. $11.7304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698323 CMS
AbbVie Inc. $13.1904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698317 CMS
Esperion Therapeutics, Inc. $16.9904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838355633 CMS
AbbVie Inc. $3.5304/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795698311 CMS
Amgen Inc. $22.9204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825719975 CMS
Lilly USA, LLC $19.3504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818725059 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.6604/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763535708 CMS
PFIZER INC. $16.3704/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832677857 CMS
AstraZeneca Pharmaceuticals LP $13.2404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829631169 CMS
Novo Nordisk Inc $10.0604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811288929 CMS
Eisai Inc. $12.9104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817904105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,060.99 147
PY2020 $2,114.17 144
PY2021 $2,356.41 148
PY2022 $1,713.33 101
PY2023 $2,255.92 121
PY2024 $2,429.97 124
PY2025 $1,924.62 100

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,672.41 7
PY2025 Principal investigator $1,011,404.90 161
PY2024 Recipient $34,409.57 3
PY2024 Principal investigator $290,464.86 32
PY2023 Principal investigator $714,905.39 52
PY2022 Principal investigator $1,344,914.20 146
PY2021 Principal investigator $1,104,673.29 161
PY2020 Principal investigator $458,634.55 248
PY2019 Recipient $1,360.79 16
PY2019 Principal investigator $589,691.29 136

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.00 12/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184280700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 12/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184280702
Principal investigator 1 Genentech, Inc. $1,895.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,246.75 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,097.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274510
Principal investigator 1 Genentech, Inc. $5,672.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,534.75 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.90 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,072.25 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32,787.45 11/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184265561
Principal investigator 1 Genentech, Inc. $250.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,493.50 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,922.45 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,128.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,857.95 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,849.50 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $492.75 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263605
Principal investigator 1 Genentech, Inc. $399.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,506.95 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261247
Principal investigator 1 Genentech, Inc. $1,895.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567792
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567845
Principal investigator 1 Genentech, Inc. $1,436.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567885
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567938
Principal investigator 1 Genentech, Inc. $1,409.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567978
Principal investigator 1 Genentech, Inc. $3,531.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568090
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568458
Principal investigator 1 Genentech, Inc. $2,154.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568646
Principal investigator 1 Genentech, Inc. $4,074.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568711
Principal investigator 1 Hoffmann-La Roche Limited $4,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569038
Principal investigator 1 Hoffmann-La Roche Limited $12,320.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,905.07 11/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,160.00 10/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253805
Principal investigator 1 Amgen Inc. $25,908.00 10/24/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638801
Principal investigator 1 Amgen Inc. $65,442.74 10/24/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,151.82 10/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,283.17 10/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $223,921.80 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32,873.85 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,938.00 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,072.25 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.02 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,431.25 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,890.00 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,118.69 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,987.05 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,425.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $741.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,296.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.85 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.50 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $768.15 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.90 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 10/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 09/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184242467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,118.69 09/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240624
Principal investigator 1 Genentech, Inc. $4,641.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566977
Principal investigator 1 Genentech, Inc. $18,738.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 08/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226321
Principal investigator 1 Amgen Inc. $5,686.50 07/28/2025 Non-covered Recipient Entity
ACCELLACARE CHARLESTON
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,740.77 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.50 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.80 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $477.90 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.35 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $230.85 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,191.75 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,626.75 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218075
Principal investigator 1 Genentech, Inc. $1,774.00 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 07/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217234
Principal investigator 1 Genentech, Inc. $6,728.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567106
Principal investigator 1 Amgen Inc. $15,988.08 07/08/2025 Non-covered Recipient Entity
ACCELLACARE CHARLESTON
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638692
Principal investigator 1 F. Hoffmann-La Roche AG $531.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566422
Principal investigator 1 F. Hoffmann-La Roche AG $54.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566533
Principal investigator 1 H. Lundbeck A S $1,053.02 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771520
Principal investigator 1 H. Lundbeck A S $350.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771548
Principal investigator 1 F. Hoffmann-La Roche AG $887.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566356
Principal investigator 1 F. Hoffmann-La Roche AG $3,548.80 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566417
Principal investigator 1 F. Hoffmann-La Roche AG $2,500.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566475
Principal investigator 1 F. Hoffmann-La Roche AG $531.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,784.43 06/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184205887
Principal investigator 1 Eli Lilly and Company $9,811.00 06/10/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187888794
Principal investigator 1 H. Lundbeck A S $83.57 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770730
Principal investigator 1 H. Lundbeck A S $2,284.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770751
Principal investigator 1 H. Lundbeck A S $295.92 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770778
Principal investigator 1 H. Lundbeck A S $212.35 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770789
Principal investigator 1 H. Lundbeck A S $88.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770801
Principal investigator 1 H. Lundbeck A S $328.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770809
Principal investigator 1 H. Lundbeck A S $137.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,784.43 06/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204049
Principal investigator 1 F. Hoffmann-La Roche AG $1,774.00 05/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566343
Principal investigator 1 GlaxoSmithKline, LLC. $2,436.75 05/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138078
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,837.57 05/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.00 05/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 05/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194259
Principal investigator 1 F. Hoffmann-La Roche AG $3,441.00 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,213.73 05/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184192745
Recipient Corcept Therapeutics $302.47 05/03/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214161989
Recipient Corcept Therapeutics $71.74 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162045
Recipient Corcept Therapeutics $76.44 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162118
Recipient Corcept Therapeutics $98.62 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162155
Recipient Corcept Therapeutics $32.67 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162191
Recipient Corcept Therapeutics $743.54 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162013
Recipient Corcept Therapeutics $346.93 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,083.51 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190769
Principal investigator 1 GlaxoSmithKline, LLC. $3,598.60 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,282.38 04/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184185253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,887.13 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183466
Principal investigator 1 H. Lundbeck A S $3,594.00 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,061.42 04/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,292.65 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174606
Principal investigator 1 H. Lundbeck A S $4,236.00 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170910
Principal investigator 1 H. Lundbeck A S $3,651.00 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,376.59 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156768
Principal investigator 1 Eli Lilly and Company $164.70 02/25/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187887622
Principal investigator 1 GlaxoSmithKline, LLC. $6,211.10 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.50 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $484.65 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.85 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $949.32 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $383.40 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.50 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76.95 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $284.85 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,292.65 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152998
Principal investigator 1 H. Lundbeck A S $21,906.00 02/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766971
Principal investigator 1 Eli Lilly and Company $500.00 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187889546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,083.94 01/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149798
Principal investigator 1 Eli Lilly and Company $3,900.12 01/27/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187889540
Principal investigator 1 GlaxoSmithKline, LLC. $10,602.00 01/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192137263
Principal investigator 1 Eli Lilly and Company $164,154.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187887616
Principal investigator 1 Eli Lilly and Company $26,656.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187888134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,686.36 01/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184147517
Principal investigator 1 GlaxoSmithKline, LLC. $921.00 01/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138071